ProShare Advisors LLC Buys Shares of 13,983 Enfusion, Inc. (NYSE:ENFN)

ProShare Advisors LLC purchased a new stake in shares of Enfusion, Inc. (NYSE:ENFN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 13,983 shares of the company’s stock, valued at approximately $144,000.

Several other hedge funds have also recently modified their holdings of ENFN. Rhumbline Advisers lifted its holdings in shares of Enfusion by 3.0% during the 4th quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after buying an additional 1,796 shares during the period. New York State Common Retirement Fund lifted its holdings in Enfusion by 23.8% in the fourth quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock valued at $19,848,000 after acquiring an additional 370,498 shares during the period. Impax Asset Management Group plc grew its stake in shares of Enfusion by 31.5% during the 4th quarter. Impax Asset Management Group plc now owns 890,000 shares of the company’s stock valued at $9,167,000 after purchasing an additional 213,052 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Enfusion by 3.3% in the 4th quarter. Bank of New York Mellon Corp now owns 126,541 shares of the company’s stock worth $1,303,000 after purchasing an additional 4,032 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Enfusion by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 371,151 shares of the company’s stock worth $3,823,000 after purchasing an additional 5,639 shares during the period. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Trading Up 0.5%

Shares of NYSE ENFN opened at $10.85 on Tuesday. The firm has a 50 day moving average of $10.86 and a 200 day moving average of $10.81. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of 271.29, a price-to-earnings-growth ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a 12-month low of $7.83 and a 12-month high of $11.80.

Enfusion (NYSE:ENFN) last posted its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The company had revenue of $52.94 million for the quarter, compared to analysts’ expectations of $53.98 million. Sell-side analysts predict that Enfusion, Inc. will post 0.06 EPS for the current year.

Insiders Place Their Bets

In other Enfusion news, CEO Oleg Movchan sold 11,452 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $11.39, for a total value of $130,438.28. Following the sale, the chief executive officer now owns 631,847 shares in the company, valued at $7,196,737.33. The trade was a 1.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Bradley Herring sold 4,645 shares of Enfusion stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total value of $52,860.10. Following the completion of the sale, the chief financial officer now directly owns 324,689 shares in the company, valued at $3,694,960.82. This trade represents a 1.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,767 shares of company stock worth $634,743. Corporate insiders own 36.44% of the company’s stock.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.